Phase I studies investigating a new monoclonal antibody that works through the inhibition of PD-1 have shown similar levels of efficacy and safety as the current PD-1 inhibitors pembrolizumab and nivolumab, as explained here by Constantine Tam, MD, FRACP, FRCPA, of the Peter MacCallum Cancer Centre, Melbourne, Australia. However, the main area of interest in this drug would be to see its efficacy when combined with a BTK inhibitor, which is currently happening in a Phase Ib study (NCT02795182). This interview was recorded at the American Society of Hematology (ASH) Annual Meeting 2017, held in Atlanta, GA.
Novel PD-1 inhibitor and BTK inhibitor combination: tislelizumab and zanubrutinib
